Human observationalStrengtheningUpdated Jul 23, 2026
A biomarker can discriminate within one study without explaining where its signal comes from or whether performance will survive a new cohort, assay, threshold, or intended use.
- Who encounters it
- Biomarker developers, laboratory scientists, statisticians, and clinical-validation teams.
- Missing proof
- Prospective replication, prespecified thresholds, calibration across laboratories and populations, comparison with simpler models, and evidence connecting measured proteins to their biological source.
- Next decisive test
- Run a prospective external validation with a locked assay, task, threshold, and analysis plan, then test whether tissue attribution and calibration remain stable across sites and patient groups.
ProteinsHeart & LungsDiscovery
Open evidence trail →
PreclinicalEmergingUpdated Jul 23, 2026
Several preclinical cancer strategies try to concentrate immune activity near tumors, but delivery location, exposure, target engagement, and human relevance remain separate validation problems.
- Who encounters it
- Translational immunologists, drug-delivery researchers, and early-phase trial designers.
- Missing proof
- Matched local-versus-systemic comparisons, concentration and persistence measurements, direct target-engagement evidence, off-target assessment, and validation in human tissue or clinical studies.
- Next decisive test
- Test the same sequence or target with matched local and systemic delivery while measuring exposure, persistence, target engagement, host-cell effects, and safety in an appropriate translational model.
CancerPeptides
Open evidence trail →
Human diagnosticMixedUpdated Jul 23, 2026
Recent diagnostic cohorts found additional diagnoses through systematic reinterpretation, while a small long-read study did not identify diagnostic variants unavailable to short-read analysis.
- Who encounters it
- Clinical geneticists, diagnostic laboratories, rare-disease researchers, and affected families.
- Missing proof
- Larger comparative cohorts, standardized reanalysis intervals, cost and turnaround comparisons, variant-class-specific yield, and diverse populations with equivalent analytic pipelines.
- Next decisive test
- Prospectively compare updated short-read interpretation with long-read sequencing in the same unsolved cases, using locked pipelines and variant-class, cost, and diagnostic-yield endpoints.
GeneticsDiscovery
Open evidence trail →
Population surveillanceMixedUpdated Jul 22, 2026
Resistance percentages can conceal large differences in organism, specimen stream, anatomical site, patient population, culture completeness, and laboratory pathway.
- Who encounters it
- Microbiology laboratories, surveillance teams, infectious-disease researchers, and public-health planners.
- Missing proof
- Harmonized denominators, sampling completeness, comparable laboratory methods, linked clinical context, and repeated measurements that distinguish local change from case-mix change.
- Next decisive test
- Publish a prospective surveillance dataset with prespecified organism, specimen, anatomical site, setting, testing completeness, and laboratory-method strata, then test portability across sites.
Infection
Open evidence trail →
Health systemsMixedUpdated Jul 22, 2026
A main clinical or program endpoint can look similar while treatment duration, visits, cost, transport, trust, and access change substantially.
- Who encounters it
- Implementation researchers, nutrition-program teams, health systems, patients, and caregivers.
- Missing proof
- Joint measurement of clinical outcomes, relapse, time, household cost, access, and implementation fidelity in the same populations and across different settings.
- Next decisive test
- Evaluate a program prospectively with a prespecified set of clinical, time, cost, access, and caregiver-burden endpoints rather than treating recovery alone as the complete outcome.
Nutrition
Open evidence trail →
PreclinicalMixedUpdated Jul 22, 2026
Representative model collections and drug-response assays solve different validation problems; neither model fidelity nor assay agreement alone establishes clinical utility.
- Who encounters it
- Precision-oncology researchers, translational pharmacology teams, and trial-design groups.
- Missing proof
- Prospective sampling rules, representation of patients who do not generate models, reproducibility across laboratories, and blinded comparison between model predictions and patient outcomes.
- Next decisive test
- Pre-register a model-and-assay workflow, apply it before treatment selection, and compare its predictions with patient outcomes while accounting for model-generation failures and turnaround time.
DiscoveryCancer
Open evidence trail →
No bottlenecks match those filters.